General Information of the Protein
Protein ID
PT01651
Protein Name
Dihydrofolate reductase
Gene Name
DHFR
Sequence
MVGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Oxidoreductase
Function
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFR2.
    Show/Hide
Uniprot ID
Primary ID:
P00374

Secondarily ID:
B4DDD2
Q14130
Q6IRW8
    Show/Hide
Ensembl ID
ENSG00000228716
HGNC ID
HGNC:2861
Subcellular Location
Mitochondrion
Cytoplasm
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000108 , CCRF-CEM
Compound ID Compound Name Compound Formula
CP0148537
2-[[4-carboxy-4-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]butyl]carbamoyl]benzoic acid
   Show/Hide
C27H27N9O6
 1
1
IC50 = 1.1 nM
   TI
   LI
   LO
   TS
CP0238793
(S)-2-{4-[1-(2,4-Diamino-pteridin-6-ylmethyl)-propyl]-benzoylamino}-pentanedioic acid
   Show/Hide
C22H25N7O5
 1
1
IC50 = 2.6 nM
   TI
   LI
   LO
   TS
CP0053031
4-Aminofolic acid
   Show/Hide
C19H20N8O5
 1
1
IC50 = 3 nM
   TI
   LI
   LO
   TS
CP0069691
CHEBI:15640
   Show/Hide
C20H23N7O7
 1
1
Ki = 2370 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0036197
2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid
   Show/Hide
C20H22N8O5
 39
1 IC50 = 1.2 nM
2 IC50 = 1.6 nM
3 IC50 = 1.7 nM
4 IC50 = 1.97 nM
5 IC50 = 2 nM
6 IC50 = 2.1 nM
7 IC50 = 2.7 nM
8 IC50 = 3 nM
9 IC50 = 3.9 nM
10 IC50 = 4 nM
11 IC50 = 4.3 nM
12 IC50 = 5 nM
13 IC50 = 6.67 nM
14 IC50 = 7.1 nM
15 IC50 = 7.9 nM
16 IC50 = 9 nM
17 IC50 = 11.2 nM
18 IC50 = 14.5 nM
19 IC50 = 20 nM
20 IC50 = 22 nM
21 IC50 = 24 nM
22 IC50 = 24.99 nM
23 IC50 = 25 nM
24 IC50 = 30.9 nM
25 IC50 = 32.94 nM
26 IC50 = 35 nM
27 IC50 = 38 nM
28 IC50 = 40 nM
29 IC50 = 66 nM
30 IC50 = 80 nM
31 IC50 = 83 nM
32 IC50 = 1000 nM
33 IC50 = 1500 nM
34 Ki = 0.01 nM
35 Ki = 0.038 nM
36 Ki = 0.077 nM
37 Ki = 0.11 nM
38 Ki = 0.179 nM
39 Ki = 4420 nM
CP0805382
2-(4-((2,4-diamino-5-chloroquinazolin-6-yl)methylamino)benzamido)pentanedioic acid
   Show/Hide
C21H21ClN6O5
 1
1 IC50 = 3.8 nM
CP0238793
(S)-2-{4-[1-(2,4-Diamino-pteridin-6-ylmethyl)-propyl]-benzoylamino}-pentanedioic acid
   Show/Hide
C22H25N7O5
 1
1 IC50 = 4.4 nM
CP0053031
4-Aminofolic acid
   Show/Hide
C19H20N8O5
 3
1 IC50 = 11.8 nM
2 IC50 = 25 nM
3 Ki = 0.21 nM
CP0148537
2-[[4-carboxy-4-[[4-[(2,4-diaminopteridin-6-yl)methylamino]benzoyl]amino]butyl]carbamoyl]benzoic acid
   Show/Hide
C27H27N9O6
 1
1 IC50 = 12.2 nM
CP0760762
SID144917
   Show/Hide
C21H21N5O6
 1
1 IC50 = 110 nM
CP0214839
5-Amino-2-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanoic acid
   Show/Hide
C20H25N9O3
 1
1 IC50 = 160 nM
CP0688707
2-(4-((2-amino-4-hydroxyquinazolin-6-yl)methoxy)benzamido)pentanedioic acid
   Show/Hide
C21H20N4O7
 1
1 IC50 = 170 nM
CP0042321
(S)-2-(4-(2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
   Show/Hide
C20H21N5O6
 2
1 IC50 = 220 nM
2 IC50 = 1000 nM
CP0039203
US9422297, PDDF
   Show/Hide
C24H23N5O6
 5
1 IC50 = 300 nM
2 IC50 = 910 nM
3 IC50 = 1900 nM
4 IC50 = 7200 nM
5 IC50 = 22000 nM
CP0686586
2-(4-((2-amino-4-hydroxyquinazolin-6-yl)methylthio)benzamido)pentanedioic acid
   Show/Hide
C21H20N4O6S
 1
1 IC50 = 330 nM
CP0036368
(2S)-2-{[4-(2-{2-amino-4-oxo-1H,4H,7H-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid
   Show/Hide
C20H21N5O6
 7
1 IC50 = 1400 nM
2 IC50 = 1500 nM
3 IC50 = 2300 nM
4 IC50 = 6600 nM
5 IC50 = 66000 nM
6 Ki = 7 nM
7 Ki = 7.2 nM
CP0788593
2-[4-(2-Amino-6-methyl-4-oxo-4,4a,7,7a-tetrahydro-3H-pyrrolo[2,3-d]pyrimidin-5-ylsulfanyl)-benzoylamino]-pentanedioic acid
   Show/Hide
C19H21N5O6S
 1
1 IC50 = 2200 nM
CP0075932
(S)-2-(4-{[(2,4-Diamino-furo[2,3-d]pyrimidin-5-ylmethyl)-amino]-methyl}-benzoylamino)-pentanedioic acid
   Show/Hide
C20H22N6O6
 1
1 IC50 = 10000 nM
CP0358670
2-{4-[(4-Amino-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid
   Show/Hide
C19H19N7O5
 1
1 IC50 = 19000 nM
CP0297780
2-{4-[(4-Amino-2-methyl-pteridin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid
   Show/Hide
C20H21N7O5
 1
1 IC50 > 50000 nM
CP0056680
2-{4-[(2,4-Diamino-quinazolin-6-ylmethyl)-amino]-benzoylamino}-pentanedioic acid
   Show/Hide
C21H22N6O5
 1
1 Ki = 0.01 nM
Clinical Information about the Protein
Target 1 ( Dihydrofolate reductase (DHFR) )
Target Type Successful Target
Disease 5 Target-related Diseases  5
1 Pulmonary and extrapulmonary tuberculosis [ICD-11: 1B10.Z]
2 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
3 Urinary tract infection [ICD-11: GC08]
4 Bacterial infection [ICD-11: 1A00-1C4Z]
5 Bladder cancer [ICD-11: 2C94]
Approved Drug(s) 3 Approved Drugs  3
1 Aminosalicylic Acid Approved
Pulmonary and extrapulmonary tuberculosis
2 Leucovorin Calcium Approved
Solid tumour/cancer
3 Trimethoprim Approved
Urinary tract infection
Clinical Trial Drug(s) 2 Clinical Trial Drugs  2
1 Iclaprim Phase 3
Bacterial infection
2 PIRITREXIM Phase 2
Bladder cancer
Preclinical Drug(s) 1 Preclinical Drug  1
1 1954U89 Preclinical
Solid tumour/cancer